Stock Research for BNIKF


Featured Broker: Ally Invest

Get the due diligence for another stock.


BNIKF Stock Chart & Research Data

The BNIKF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BNIKF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BNIKF Due diligence Resources & Stock Charts

The BNIKF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BNIKF Detailed Price Forecast - CNN Money CNN View BNIKF Detailed Summary - Google Finance
Yahoo View BNIKF Detailed Summary - Yahoo! Finance Zacks View BNIKF Stock Research & Analysis -

Stock Analysis

TradeIdeas View BNIKF Trends & Analysis - Trade-Ideas Barrons View BNIKF Major Holders - Barrons
NASDAQ View BNIKF Call Transcripts - NASDAQ Seeking View BNIKF Breaking News & Analysis - Seeking Alpha
Spotlight View BNIKF Annual Report - OTC Report View BNIKF OTC Short Report -
TradeKing View BNIKF Fundamentals - TradeKing Charts View BNIKF SEC Filings - Bar Chart
WSJ View Historical Prices for BNIKF - The WSJ Morningstar View Performance/Total Return for BNIKF - Morningstar
MarketWatch View the Analyst Estimates for BNIKF - MarketWatch CNBC View the Earnings History for BNIKF - CNBC
StockMarketWatch View the BNIKF Earnings - StockMarketWatch MacroAxis View BNIKF Buy or Sell Recommendations - MacroAxis
Bullish View the BNIKF Bullish Patterns - American Bulls Short Pains View BNIKF Short Pain Metrics -

Social Media Mentions

StockTwits View BNIKF Stock Mentions - StockTwits PennyStocks View BNIKF Stock Mentions - PennyStockTweets
Twitter View BNIKF Stock Mentions - Twitter Invest Hub View BNIKF Investment Forum News - Investor Hub
Yahoo View BNIKF Stock Mentions - Yahoo! Message Board Seeking Alpha View BNIKF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BNIKF - Insider Cow View Insider Transactions for BNIKF - Insider Cow
CNBC View BNIKF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BNIKF - OTC Markets
Yahoo View Insider Transactions for BNIKF - Yahoo! Finance NASDAQ View Institutional Holdings for BNIKF - NASDAQ

Stock Charts

FinViz View BNIKF Stock Insight & Charts - StockCharts View BNIKF Investment Charts -
BarChart View BNIKF Stock Overview & Charts - BarChart Trading View View BNIKF User Generated Charts - Trading View

Latest Financial News for BNIKF

ASX/NASDAQ Announcement
Posted on Tuesday April 24, 2018

NASDAQ: BNTCW) today provided an update on its two lead programs in head and neck squamous cell carcinoma (HNSCC) and oculopharyngeal muscular dystrophy (OPMD).  This update should be read in conjunction with the latest corporate presentation which can be found on the Company's website. The first clinical site has now been opened in Australia and the Company anticipates having additional Australian sites open later this month.  Regulatory review with the Ministry of Health is ongoing in Russia and the Company expects approval at the end of May.

Benitec Biopharma Launches its Phase 2 Oncology Study in Australia
Posted on Monday March 05, 2018

NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy and its patented gene-silencing technology named ddRNAi or 'expressed RNAi', today announced the start of its Phase 2 clinical study in Australia with BB-401 as a treatment for patients with head and neck squamous cell carcinoma (HNSCC). The Phase 2 open label study has been designed to explore the safety, tolerability and efficacy of BB-401 following intratumoral injections into the lesions of patients with recurrent or metastatic HNSCC.  The study will enrol up to 30 patients at 5-8 sites across Australia and Russia.  The trial is registered on with the identifier: NCT03433027, where more details can be found.

Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update
Posted on Thursday February 22, 2018

SYDNEY , Feb. 22, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative ...

Federal R&D Tax Credit Received
Posted on Tuesday January 23, 2018

SYDNEY , Jan. 23, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received a $4,112,058 cash refund for the year ended 2017 under the Federal ...

Enter a stock symbol to view the stock details.